Last reviewed · How we verify
NCT05752097
[18F]AlF-NOTA-FAPI-04 PET/CT in Inflammation and Fibrosis in Renal Diseases
trial testing [18F]AlF-NOTA-FAPI-04 PET/CT examination in 18F-FAPI PET/CT Examination in 30 participants. Status unknown.
30 August 2024
Quick facts
| Lead sponsor | Sichuan Provincial People's Hospital |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 30 |
| Start date | 1 February 2023 |
| Primary completion | 30 August 2024 |
| Estimated completion | 30 November 2024 |
| Sites | 1 location across China |
Drugs / interventions tested
- [18F]AlF-NOTA-FAPI-04 PET/CT examination
- Renal puncture biopsy
Conditions studied
- 18F-FAPI PET/CT Examination — all drugs for 18F-FAPI PET/CT Examination →
- Renal Puncture Biopsy — all drugs for Renal Puncture Biopsy →
Sponsor
Sichuan Provincial People's Hospital
Who can join
Adults 10 to 80, any sex, with 18F-FAPI PET/CT Examination or Renal Puncture Biopsy. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The goal of this observational study is to explore the feasibility of using 18F-labeled FAP molecular probe for PET/CT imaging (18F-FAPI PET/CT) to accurately evaluate inflammation and fibrosis in renal diseases. The main questions it aims to answer are: * Can 18F-FAPI PET/CT accurately evaluate the inflammation and fibrosis of kidney disease? * What is the value of 18F-FAPI PET/CT as a non-invasive assessment of inflammation and fibrosis in kidney disease? Participants will receive \[18F\]AlF-NOTA-FAPI-04 PET/CT and renal aspiration biopsy.
Publications & conference data
4 peer-reviewed publications reference this trial (live from Europe PMC):
-
From basic research to clinical application: targeting fibroblast activation protein for cancer diagnosis and treatment.
Zhang Z, Tao J, Qiu J, Cao Z, et al · · 2024 · cited 21× · PMID 37726505 · DOI 10.1007/s13402-023-00872-z -
[<sup>18</sup>F] AlF-NOTA-FAPI-04 PET/CT for non-invasive assessment of tubular injury in kidney diseases.
Wang H, Zhang P, Wang W, He L, et al · · 2024 · cited 9× · PMID 38803395 · DOI 10.1093/ckj/sfae064 -
Non-invasive assessment of IgA nephropathy severity with [<sup>18</sup>F]AlF-NOTA-FAPI-04 PET/CT imaging.
Wang H, He L, Feng L, Zhang W, et al · · 2024 · cited 6× · PMID 39664991 · DOI 10.1093/ckj/sfae340 -
Pathways and challenges in the clinical translational of radiopharmaceuticals for pediatric investigations.
Stauff E, Karimi H, Kecskemethy HH, Shaffer TH, et al · · 2025 · PMID 41282032 · DOI 10.3389/fmed.2025.1658588
Verify or expand the search:
- PubMed search for NCT05752097
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other Sichuan Provincial People's Hospital trials
Trials by the same sponsor.
- NCT07298525 — Safety Exploration and Evaluation of Dexmedetomidine Hydrochloride Nasal Spray for Pre-anesthesia Sedation in Low-Monito · Phase 4 · not yet recruiting
- NCT07175363 — Butorphanol for Pain Relief After Cesarean Section: A Retrospective Study · not yet recruiting
- NCT07106996 — Mechanism of Red Yeast Rice Regulating Intestinal Indole Metabolism Pathway to Improve Chronic Inflammation in Polycysti · EARLY_PHASE1 · recruiting
- NCT07082946 — Mechanisms of Perioperative Systemic Inflammation in the Development of PND in Cirrhotic Patients · not yet recruiting
- NCT06821633 — Investigating the Retardation Effect of OCTA-Guided Targeted Photocoagulation on the Progression of Non-Perfusion Areas · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05752097 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Sichuan Provincial People's Hospital
- Last refreshed: 24 January 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05752097.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing